Skip to main content
Biofrontera Inc. logo

Biofrontera Inc. — Investor Relations & Filings

Ticker · BFRI ISIN · US09077D1000 LEI · 984500444S8BE1EF0179 US Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2026-05-14 Earnings Release
Country US United States of America
Listing US BFRI

About Biofrontera Inc.

https://www.biofrontera-us.com/

Biofrontera Inc. is a biopharmaceutical company that commercializes a portfolio of pharmaceutical products for the treatment of dermatological conditions. The company specializes in photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used to treat actinic keratoses, a type of pre-cancerous skin lesion, and impetigo, a bacterial skin infection. Biofrontera focuses on establishing PDT as a standard of care in dermatology and utilizes a proprietary nanoemulsion technology to improve the stability and skin penetration of its formulations, potentially increasing clinical efficacy.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 84% confidence The document is a Form 8-K “Current Report” under Item 2.02 “Results of Operations and Financial Condition,” announcing and furnishing a press release with the company’s quarterly financial results. This matches the definition of an Earnings Release (ER): an initial announcement of periodic financial results. It is not the full financial report itself, but the announcement of the results, so ER is the correct category. Q1 2026
2026-05-14 English
10-K - Biofrontera Inc. (0001858685) (Filer)
Annual Report FY 2025
2026-03-19 English
8-K - Biofrontera Inc. (0001858685) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It specifically includes Item 2.02 "Results of Operations and Financial Condition," indicating the company issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2025. The document also references a press release as Exhibit 99.1. The Form 8-K is used to report unscheduled material events or corporate changes, including earnings releases. Given the content focuses on announcing financial results and includes a press release with key highlights, this fits the definition of an Earnings Release (ER). The document length is about 5141 characters, which is consistent with a typical 8-K earnings release announcement. Therefore, the classification is Earnings Release (ER) with high confidence.
2026-03-19 English
4 - Biofrontera Inc. (0001858685) (Issuer)
Director's Dealing
2026-03-07 English
4 - Biofrontera Inc. (0001858685) (Issuer)
Director's Dealing
2026-03-07 English
4 - Biofrontera Inc. (0001858685) (Issuer)
Director's Dealing
2026-03-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.